NIH Guide: Weekly Index for April 2, 2021

Funding Opportunities

• Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)
  (PA-21-199)
  National Institute of Mental Health
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): Multiple dates, see announcement.
• Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
  (PA-21-200)
  National Institute of Mental Health
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
• Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)
  (PA-21-201)
  National Institute of Mental Health
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
• Short-Term Mentored Research Career Enhancement Award to Promote Diversity (K18 No Independent Clinical Trials)
  (PA-21-214)
  National Human Genome Research Institute
  Application Receipt Date(s): June 12, 2021, February 12, 2022, February 12, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
  (PAR-21-162)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): August 10, 2021, February 9, 2022, August 9, 2022, February 9, 2023, August 9, 2023, February 9, 2024
• Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed)
  (PAR-21-185)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): May 28, 2021; September 24, 2021; January 27, 2022; May 27, 2022; September 21, 2022; January 27, 2023; May 26 2023; September 26, 2023. January 29, 2024.
• NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed)
  (PAR-21-187)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): May 28, 2021; September 24, 2021; January 27, 2022; May 27, 2022; September 21, 2022; January 27, 2023; May 26, 2023; September 26, 2023; January 29, 2024; September 30, 2024 apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)
  (PAR-21-196)
  National Institute of General Medical Sciences
  Application Receipt Date(s): October 14, 2021; October 14, 2022; October 13, 2023
• NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (PAR-21-197)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Multiple dates, see announcement.
• Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
  (PAR-21-210)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)
  (PAR-21-211)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-009)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
• Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed)
  (RFA-AI-21-012)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
• Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-019)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): August 24, 2021
• Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)
  (RFA-AI-21-023)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)
  (RFA-AI-21-024)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)
  (RFA-AI-21-025)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
  (RFA-AR-21-015)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Allergy and Infectious Diseases
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)
  (RFA-AR-21-016)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Allergy and Infectious Diseases
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
• Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)
  (RFA-DA-22-002)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
• Nutrition Obesity Research Centers (P30 Clinical Trial Optional)
  (RFA-DK-21-015)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
• Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)
  (RFA-HD-22-010)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 29, 2021
• User-Based Design to Aid in Contraceptive Development by Small Business (R43 Clinical Trial Not Allowed)
  (RFA-HD-22-019)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 29, 2021
• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial Not Allowed)
  (RFA-HG-21-006)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)
  (RFA-HG-21-007)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
  (RFA-HG-21-008)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
  (RFA-RM-21-012)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): Multiple dates, see announcement.
• Intramural - Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2/UH3 Clinical Trial Not Allowed)
  (RFA-TR-21-015)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Multiple dates, see announcement.